These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 38334807)

  • 61. BCL-2 as therapeutic target for hematological malignancies.
    Perini GF; Ribeiro GN; Pinto Neto JV; Campos LT; Hamerschlak N
    J Hematol Oncol; 2018 May; 11(1):65. PubMed ID: 29747654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.
    Westin GF; Dias AL; Go RS
    Curr Hematol Malig Rep; 2016 Aug; 11(4):271-9. PubMed ID: 27177742
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Patterns of hematological and non-hematological malignancies in bone marrow in a tertiary care hospital in Nepal--11 years study.
    Ghartimagar D; Ghosh A; Narasimhan R; Talwar OP
    Nepal Med Coll J; 2012 Sep; 14(3):187-92. PubMed ID: 24047012
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies.
    Fulda S
    Leukemia; 2012 Jun; 26(6):1155-65. PubMed ID: 22230799
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.
    Mynott RL; Habib A; Best OG; Wallington-Gates CT
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108836
    [TBL] [Abstract][Full Text] [Related]  

  • 66. miRNAs mediated drug resistance in hematological malignancies.
    Peixoto da Silva S; Caires HR; Bergantim R; Guimarães JE; Vasconcelos MH
    Semin Cancer Biol; 2022 Aug; 83():283-302. PubMed ID: 33757848
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.
    Misso G; Zarone MR; Grimaldi A; Di Martino MT; Lombardi A; Kawasaki H; Stiuso P; Tassone P; Tagliaferri P; Caraglia M
    Curr Drug Targets; 2017; 18(1):35-55. PubMed ID: 27280795
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 69. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.
    Camus V; Miloudi H; Taly A; Sola B; Jardin F
    J Hematol Oncol; 2017 Feb; 10(1):47. PubMed ID: 28196522
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular Immunology in Hematological Disorders.
    Takami A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076973
    [TBL] [Abstract][Full Text] [Related]  

  • 71. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.
    Bergaggio E; Riganti C; Garaffo G; Vitale N; Mereu E; Bandini C; Pellegrino E; Pullano V; Omedè P; Todoerti K; Cascione L; Audrito V; Riccio A; Rossi A; Bertoni F; Deaglio S; Neri A; Palumbo A; Piva R
    Blood; 2019 Jan; 133(2):156-167. PubMed ID: 30455381
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Delineating the role of nuclear receptors in colorectal cancer, a focused review.
    Manickasamy MK; Jayaprakash S; Girisa S; Kumar A; Lam HY; Okina E; Eng H; Alqahtani MS; Abbas M; Sethi G; Kumar AP; Kunnumakkara AB
    Discov Oncol; 2024 Feb; 15(1):41. PubMed ID: 38372868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular Players in Hematologic Tumor Cell Trafficking.
    Redondo-Muñoz J; García-Pardo A; Teixidó J
    Front Immunol; 2019; 10():156. PubMed ID: 30787933
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
    Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
    Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Polymeric nanomedicines targeting hematological malignancies.
    Gu W; Qu R; Meng F; Cornelissen JJLM; Zhong Z
    J Control Release; 2021 Sep; 337():571-588. PubMed ID: 34364920
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
    Sharma A; Singh V; Deol A
    Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of tumor-associated macrophages in hematological malignancies.
    Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
    Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies.
    Bazzoni R; Tanasi I; Turazzi N; Krampera M
    Stem Cells; 2022 Jul; 40(7):619-629. PubMed ID: 35442447
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Angiogenesis in hematologic malignancies and its clinical implications.
    Yang R; Han ZC
    Int J Hematol; 2002 Apr; 75(3):246-56. PubMed ID: 11999351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.